<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence of postengraftment invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> (IA) in hematopoietic stem cell transplant (HSCT) recipients increased during the 1990s </plain></SENT>
<SENT sid="1" pm="."><plain>We determined risks for IA and outcomes among 1682 patients who received HSCTs between January 1993 and December 1998 </plain></SENT>
<SENT sid="2" pm="."><plain>Risk factors included host variables (age, underlying disease), transplant variables (stem cell source), and late complications (<z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> [GVHD], receipt of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, secondary <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, cytomegalovirus [CMV] disease, and respiratory <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>We identified risk factors associated with IA early after transplantation (&lt;or= 40 days) and after engraftment (41-180 days) </plain></SENT>
<SENT sid="4" pm="."><plain>Older patient age was associated with an increased risk during both periods </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0005506'>Chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase was associated with low risk for early IA compared with other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0006775'>Multiple myeloma</z:hpo> was associated with an increased risk for postengraftment IA </plain></SENT>
<SENT sid="7" pm="."><plain>Use of human leukocyte antigen (HLA)-matched related (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) peripheral blood stem cells conferred protection against early IA compared with use of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> bone marrow, but use of cord blood increased the risk of IA early after transplantation </plain></SENT>
<SENT sid="8" pm="."><plain>Factors that increased risks for IA after engraftment included receipt of T cell-depleted or CD34-selected stem cell products, receipt of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001888'>lymphopenia</z:hpo>, GVHD, CMV disease, and respiratory <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infections</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Very late IA (&gt; 6 months after transplantation) was associated with <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD and CMV disease </plain></SENT>
<SENT sid="10" pm="."><plain>These results emphasize the postengraftment timing of IA; risk factor analyses verify previously recognized risk factors (GVHD, receipt of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, and <z:hpo ids='HP_0001875'>neutropenia</z:hpo>) and uncover the roles of <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> and <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in increasing the incidence of postengraftment IA in the 1990s </plain></SENT>
</text></document>